This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vertex Pharmaceuticals Incorporated
Drug Names(s): VX-148
Description: VX-148 is chemically distinct from merimepodib and it targets antiviral and autoimmune indications.
VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes.
Pink Sheet Weekly Trademark Review Feb. 24, 2015
Additional information available to subscribers only: